Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Department of Chemistry, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Mol Imaging Biol. 2023 Aug;25(4):704-719. doi: 10.1007/s11307-023-01814-9. Epub 2023 Mar 29.
Previous studies from our lab utilized an ultra-high throughput screening method to identify compound 1 as a small molecule that binds to alpha-synuclein (α-synuclein) fibrils. The goal of the current study was to conduct a similarity search of 1 to identify structural analogs having improved in vitro binding properties for this target that could be labeled with radionuclides for both in vitro and in vivo studies for measuring α-synuclein aggregates.
Using 1 as a lead compound in a similarity search, isoxazole derivative 15 was identified to bind to α-synuclein fibrils with high affinity in competition binding assays. A photocrosslinkable version was used to confirm binding site preference. Derivative 21, the iodo-analog of 15, was synthesized, and subsequently radiolabeled isotopologs [I]21 and [C]21 were successfully synthesized for use in in vitro and in vivo studies, respectively. [I]21 was used in radioligand binding studies in post-mortem Parkinson's disease (PD) and Alzheimer's disease (AD) brain homogenates. In vivo imaging of an α-synuclein mouse model and non-human primates was performed with [C]21.
In silico molecular docking and molecular dynamic simulation studies for a panel of compounds identified through a similarity search, were shown to correlate with K values obtained from in vitro binding studies. Improved affinity of isoxazole derivative 15 for α-synuclein binding site 9 was indicated by photocrosslinking studies with CLX10. Design and successful (radio)synthesis of iodo-analog 21 of isoxazole derivative 15 enabled further in vitro and in vivo evaluation. K values obtained in vitro with [I]21 for α-synuclein and Aβ fibrils were 0.48 ± 0.08 nM and 2.47 ± 1.30 nM, respectively. [I]21 showed higher binding in human postmortem PD brain tissue compared with AD tissue, and low binding in control brain tissue. Lastly, in vivo preclinical PET imaging showed elevated retention of [C]21 in PFF-injected mouse brain. However, in PBS-injected control mouse brain, slow washout of the tracer indicates high non-specific binding. [C]21 showed high initial brain uptake in a healthy non-human primate, followed by fast washout that may be caused by rapid metabolic rate (21% intact [C]21 in blood at 5 min p.i.).
Through a relatively simple ligand-based similarity search, we identified a new radioligand that binds with high affinity (<10 nM) to α-synuclein fibrils and PD tissue. Although the radioligand has suboptimal selectivity for α-synuclein towards Aβ and high non-specific binding, we show here that a simple in silico approach is a promising strategy to identify novel ligands for target proteins in the CNS with the potential to be radiolabeled for PET neuroimaging studies.
本实验室之前的研究利用超高通量筛选方法鉴定出化合物 1 是一种与α-突触核蛋白(α-synuclein)纤维结合的小分子。本研究的目的是对 1 进行相似性搜索,以鉴定出具有改善的体外结合特性的结构类似物,这些类似物可被放射性核素标记,用于体外和体内研究,以测量α-突触核蛋白聚集体。
使用 1 作为先导化合物进行相似性搜索,确定异噁唑衍生物 15 与α-突触核蛋白纤维具有高亲和力的竞争结合测定。使用光交联版本来确认结合位点偏好。合成了碘代类似物 21,随后成功合成了放射性同位素标记的[I]21 和[C]21,分别用于体外和体内研究。[I]21 用于死后帕金森病(PD)和阿尔茨海默病(AD)脑匀浆的放射性配体结合研究。使用[C]21 对α-突触核蛋白小鼠模型和非人类灵长类动物进行体内成像。
通过相似性搜索鉴定的一组化合物的计算机分子对接和分子动力学模拟研究表明,与体外结合研究中获得的 K 值相关。用 CLX10 进行光交联研究表明,异噁唑衍生物 15 对α-突触核蛋白结合位点 9 的亲和力增强。异噁唑衍生物 15 的碘代类似物 21 的设计和成功(放射性)合成使进一步的体外和体内评估成为可能。用[I]21 体外测定的α-突触核蛋白和 Aβ纤维的 K 值分别为 0.48±0.08 nM 和 2.47±1.30 nM。与 AD 组织相比,[I]21 在人死后 PD 脑组织中的结合更高,在对照脑组织中的结合较低。最后,体内临床前 PET 成像显示 PFF 注射的小鼠脑中[C]21 的保留增加。然而,在 PBS 注射的对照小鼠脑内,示踪剂的缓慢洗脱表明存在高非特异性结合。在健康的非人类灵长类动物中,[C]21 表现出较高的初始脑摄取,随后快速洗脱,这可能是由于代谢率高(5 分钟时血液中 21%的完整[C]21)。
通过相对简单的基于配体的相似性搜索,我们鉴定出一种新的放射性配体,该配体与α-突触核蛋白纤维具有高亲和力(<10 nM)和 PD 组织。尽管该放射性配体对 Aβ的α-突触核蛋白选择性较差,且非特异性结合较高,但我们在此表明,简单的计算机模拟方法是一种有前途的策略,可以鉴定中枢神经系统中目标蛋白的新型配体,这些配体有可能被放射性核素标记用于正电子发射断层扫描神经影像学研究。